Literature DB >> 12181439

Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation.

Dean J Naisbitt1, John Farrell, S Fraser Gordon, James L Maggs, Christoph Burkhart, Werner J Pichler, Munir Pirmohamed, B Kevin Park.   

Abstract

Treatment with sulfamethoxazole (SMX) can lead to hypersensitivity reactions. T cells from hypersensitive patients recognize either the parent drug and/or the reactive nitroso (SMX-NO) metabolite. In this study, using a novel in vitro rat splenocyte assay, we have investigated the toxicological and immunological consequences of cell surface haptenation by SMX-NO. SMX-NO was found to be unstable in solution; spontaneous transformation yielded appreciable amounts of SMX-hydroxylamine, nitro-SMX, and the previously unknown azoxy and azo dimers within 15 min. Irreversible binding of SMX-NO to cellular protein was demonstrated by flow cytometry, with haptenation being greater on the surface of antigen-presenting cells than on T cells. The consequences of irreversible binding of SMX-NO were examined in two ways. First, haptenation above a threshold level led to a proportionate increase in cell death (both apoptosis and necrosis). Indeed, the cells that became haptenated were the same as those that underwent necrotic cell death. Second, sensitized splenocytes proliferated in the presence of major histocompatibility complex (MHC)-restricted antigen derived from both viable and dead cells haptenated with low and high levels of SMX-NO, respectively. However, direct modification of MHC by SMX-NO was not the mechanism of antigen presentation. The antigenic threshold of SMX-NO for T-cell proliferation and toxicity was estimated to be between 0.5 and 1 microM and 5 to 10 microM, respectively. The potential of SMX-NO to generate a potent antigen and cause cytotoxicity may in combination provide the signals necessary to induce a hypersensitivity reaction to SMX.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12181439     DOI: 10.1124/mol.62.3.628

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  25 in total

Review 1.  Role of bioactivation in drug-induced hypersensitivity reactions.

Authors:  Joseph P Sanderson; Dean J Naisbitt; B Kevin Park
Journal:  AAPS J       Date:  2006-02-03       Impact factor: 4.009

2.  Antibacterial activities of sulfamethoxazolyl-azo-phenols and their Cu(II) complexes along with molecular docking properties.

Authors:  Nilima Sahu; Sudipa Mondal; Nayim Sepay; Suvroma Gupta; Elena Torres-Lopez; Shinnosuke Tanaka; Takashiro Akitsu; Chittaranjan Sinha
Journal:  J Biol Inorg Chem       Date:  2017-04-28       Impact factor: 3.358

Review 3.  Hypersensitivity reactions to HIV therapy.

Authors:  Mas Chaponda; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

4.  Evaluation of sulfonamide detoxification pathways in haematologic malignancy patients prior to intermittent trimethoprim-sulfamethoxazole prophylaxis.

Authors:  Mahmoud Abouraya; James C Sacco; Brad S Kahl; Lauren A Trepanier
Journal:  Br J Clin Pharmacol       Date:  2011-04       Impact factor: 4.335

Review 5.  Drug hypersensitivity in HIV infection.

Authors:  Jonny Peter; Phuti Choshi; Rannakoe J Lehloenya
Journal:  Curr Opin Allergy Clin Immunol       Date:  2019-08

6.  Influence of NAT2 polymorphisms on sulfamethoxazole pharmacokinetics in renal transplant recipients.

Authors:  Hideaki Kagaya; Masatomo Miura; Takenori Niioka; Mitsuru Saito; Kazuyuki Numakura; Tomonori Habuchi; Shigeru Satoh
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

7.  Drug antigenicity, immunogenicity, and costimulatory signaling: evidence for formation of a functional antigen through immune cell metabolism.

Authors:  Ayman Elsheikh; Sidonie N Lavergne; J Luis Castrejon; John Farrell; Haiyi Wang; Jean Sathish; Werner J Pichler; B Kevin Park; Dean J Naisbitt
Journal:  J Immunol       Date:  2010-10-27       Impact factor: 5.422

8.  "Danger" conditions increase sulfamethoxazole-protein adduct formation in human antigen-presenting cells.

Authors:  S N Lavergne; H Wang; H E Callan; B K Park; D J Naisbitt
Journal:  J Pharmacol Exp Ther       Date:  2009-08-07       Impact factor: 4.030

9.  Immunogenicity of trimethoprim/sulfamethoxazole in a macaque model of HIV infection.

Authors:  Yat Yee Wong; Eva G Rakasz; David J Gasper; Thomas C Friedrich; Lauren A Trepanier
Journal:  Toxicology       Date:  2016-08-23       Impact factor: 4.221

10.  Bioactivation of Trimethoprim to Protein-Reactive Metabolites in Human Liver Microsomes.

Authors:  Jennifer L Goldman; Yakov M Koen; Steven A Rogers; Kelin Li; James S Leeder; Robert P Hanzlik
Journal:  Drug Metab Dispos       Date:  2016-07-25       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.